Actions

Weight loss injections Philadelphia

From W8MD weight loss and sleep centers

Affordable W8MD medical weight loss options including Semaglutide, Tirzepatide, GLP-1 shots, traditional medications, lifestyle medicine, sleep care, reviews, and long-term weight maintenance

Affordable GLP-1 weight loss shots at W8MD
Affordable GLP-1 weight loss shots at W8MD
W8MD Weight Loss, Sleep and MedSpa offers affordable physician-supervised medical weight loss, GLP-1 injections, sleep medicine, and MedSpa services
Specialty Obesity medicine, medical weight loss, sleep medicine, nutrition counseling, lifestyle medicine
Uses Obesity, overweight, weight loss, weight loss maintenance, insulin resistance, prediabetes, type 2 diabetes, sleep apnea, metabolic syndrome






Related W8MD Weight Loss, Sleep and MedSpa, NYC medical weight loss, Philadelphia weight loss doctor, GLP-1 maintenance therapy, weight loss maintenance
W8MD helps patients lose weight using evidence-based medical weight-loss options and long-term maintenance planning.
W8MD success stories include patients who lost substantial weight and maintained results long term.
W8MD may combine GLP-1 weight loss injections, traditional prescription medications, nutrition counseling, and lifestyle medicine.
Weight loss success stories Philadelphia

Affordable GLP-1 weight loss shots at W8MD refers to physician-supervised medical weight-loss programs at W8MD Weight Loss, Sleep and MedSpa that may include GLP-1 weight loss injections, Semaglutide, Tirzepatide, traditional prescription diet pills, meal replacements, nutrition counseling, sleep apnea care, lifestyle medicine, and long-term weight loss maintenance.

W8MD is a physician-supervised weight loss, sleep, and MedSpa center established in 2011. W8MD has helped thousands of patients lose weight and maintain long-term results. W8MD’s approach is designed not only to help patients lose weight, but also to help keep the weight off through regular follow-up, maintenance medication planning, nutrition support, restorative sleep care, behavior modification, and relapse-prevention strategies.

Overview

GLP-1 weight loss injections have changed the treatment of obesity and overweight by helping many patients reduce appetite, reduce cravings, improve satiety, reduce food noise, and lose clinically meaningful weight. W8MD offers affordable access to physician-supervised GLP-1 options for eligible patients, while also providing the support needed for long-term success.

W8MD may help patients with:

Promotional GLP-1 pricing at W8MD

Affordable W8MD GLP-1 weight-loss shot specials

W8MD offers affordable physician-supervised GLP-1 weight-loss options for eligible patients.

  • Semaglutide starting as low as $29.99/week and up with insurance for qualifying medical visits.
  • Tirzepatide starting as low as $45.00/week and up with insurance for qualifying medical visits.
  • Self-pay GLP-1 options may start from $59.99/week and up when available and medically appropriate.
  • W8MD also monitors emerging incretin medications, including investigational triple-action agents such as retatrutide.
  • Pricing, medication access, insurance coverage, prior authorization, pharmacy availability, eligibility, dosing, and program details vary by patient, location, medication, and medical evaluation.

Important note on retatrutide: The correct spelling is retatrutide, not “ritatrutide.” Retatrutide is a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors and is considered investigational / experimental as of June, 2026.

Why W8MD is a natural choice for weight loss

W8MD is a natural choice for patients seeking affordable, medically supervised weight loss because it combines prescription options with lifestyle and maintenance support.

Reasons patients choose W8MD include:

  • Established in 2011
  • Helped thousands of patients
  • Physician-supervised care
  • Affordable GLP-1 specials
  • Most insurances accepted for qualifying visits
  • Semaglutide and Tirzepatide options
  • Traditional prescription diet pills
  • Nutrition counseling
  • Meal replacements
  • Low-carbohydrate and ketogenic diet support
  • Sleep apnea diagnosis and treatment
  • Long-term maintenance care
  • Weight regain prevention
  • MedSpa and wellness services
  • Brooklyn, New York City, and Philadelphia locations

Current GLP-1 and incretin options

GLP-1 and incretin-based medications work by targeting hormones involved in appetite, blood sugar, stomach emptying, and satiety.

Medication Brand names Type W8MD role Notes
Semaglutide Wegovy, Ozempic GLP-1 receptor agonist May be used for eligible patients when medically appropriate Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction in selected adults
Tirzepatide Zepbound, Mounjaro Dual GIP and GLP-1 receptor agonist May be used for eligible patients when medically appropriate Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related conditions
Liraglutide Saxenda, Victoza GLP-1 receptor agonist Alternative injectable option in selected patients Saxenda is a daily injection for chronic weight management
Retatrutide Investigational Triple GIP, GLP-1, and glucagon receptor agonist Education and pipeline monitoring only unless legally available Investigational and not FDA-approved for routine clinical use as of 2026

The FDA approved Zepbound or tirzepatide for chronic weight management in adults with obesity or overweight with at least one weight-related condition, together with reduced-calorie diet and increased physical activity.FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.November 8, 2023.

The FDA approved Wegovy or semaglutide to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.

Semaglutide at W8MD

Semaglutide is a GLP-1 receptor agonist used in obesity medicine and diabetes care depending on product and indication. For weight loss, semaglutide can reduce hunger, increase fullness, reduce food noise, and support calorie reduction.

W8MD may help with:

  • Semaglutide eligibility evaluation
  • Medical visit and BMI review
  • Insurance visit support when available
  • Dose titration when appropriate
  • Side-effect monitoring
  • Nutrition counseling
  • Protein and hydration planning
  • Constipation prevention
  • Weight-loss tracking
  • Long-term maintenance planning

Semaglutide promotional pricing

Semaglutide special

  • Semaglutide starting as low as $29.99/week and up with insurance for qualifying medical visits.
  • Eligibility, insurance coverage, dosing, medication access, and pricing vary.
  • Medical evaluation is required.

Tirzepatide at W8MD

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is available as Zepbound for chronic weight management and Mounjaro for type 2 diabetes, depending on indication and prescribing decision.

W8MD may help with:

  • Tirzepatide eligibility evaluation
  • Medical supervision
  • Dose titration
  • Side-effect monitoring
  • Insurance and prior authorization support when available
  • Nutrition counseling
  • Protein intake planning
  • Hydration and constipation prevention
  • Weight-loss maintenance

Tirzepatide promotional pricing

Tirzepatide special

  • Tirzepatide starting as low as $45.00/week and up with insurance for qualifying medical visits.
  • Eligibility, insurance coverage, dosing, medication access, and pricing vary.
  • Medical evaluation is required.

Emerging triple-action incretin shots

Retatrutide is an investigational triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. It is sometimes described as a “triple-action” or “triple agonist” weight-loss injection.

A 2023 phase 2 trial published in the New England Journal of Medicine reported substantial body-weight reductions in adults with obesity treated with retatrutide for 48 weeks."Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.

In May 2026, Lilly announced phase 3 TRIUMPH-1 results in which participants on 12 mg retatrutide lost an average of 70.3 pounds, or 28.3%, over 80 weeks.Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial(link). Eli Lilly and Company.May 21, 2026.

Please note retatrutide is investigational as of June, 2026 and is off-label use if prescribed. W8MD can educate the patients on this and other GLP-1 weight loss injections.

Traditional prescription weight-loss medications at W8MD

GLP-1 medications are not the only option. W8MD also offers traditional prescription weight-loss medications when medically appropriate.

Options may include:

Traditional medications may be useful for patients who:

  • Cannot access GLP-1 medications
  • Need lower-cost options
  • Have weight regain after stopping GLP-1 therapy
  • Need appetite control
  • Have cravings or food noise
  • Need combination maintenance
  • Are transitioning into long-term maintenance

Meal replacements and W8MD weight-loss diet

W8MD may use meal replacements and structured eating plans to support weight loss. Meal replacements can help patients reduce calories, maintain protein intake, simplify meal planning, and avoid skipped meals.

W8MD nutrition tools may include:

Why W8MD helps patients keep weight off

Many patients can lose weight temporarily, but keeping it off requires a maintenance plan. W8MD emphasizes long-term follow-up and relapse prevention.

W8MD maintenance care may include:

The STEP 1 trial extension found that after stopping once-weekly semaglutide 2.4 mg and lifestyle intervention, participants regained a substantial portion of lost weight."Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension".Diabetes, Obesity and Metabolism.2022;PMID:35441470.PMC:9542252.

The SURMOUNT-4 trial found that continued tirzepatide maintained and increased weight reduction, while withdrawal led to substantial regain."Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity".JAMA.2024;PMID:38078870.

W8MD and sleep medicine

W8MD is not just a weight-loss clinic. W8MD also provides sleep medicine services, which is important because poor sleep and untreated sleep apnea can worsen hunger, cravings, fatigue, blood pressure, insulin resistance, and weight regain.

W8MD may help with:

The FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.

W8MD reviews and patient experience

W8MD patients often describe the program as supportive, practical, and life-changing. Many patients choose W8MD because they want more than medication alone. They want medical guidance, affordable options, nutrition support, and long-term accountability.

Common patient review themes include:

  • Friendly staff
  • Supportive providers
  • Affordable options
  • Reduced hunger
  • Reduced cravings
  • Better blood pressure
  • Better blood sugar
  • Better cholesterol
  • Improved confidence
  • Long-term maintenance support
  • Practical meal plans
  • Convenient medical weight-loss visits

Featured W8MD testimonial

Fantastic program. Truly a life changer.

“FANTASTIC program! Truly a life changer! The first several months I lost on average 3 pounds a week. I have now lost 87 pounds in 10 months and I'm still losing! I can say it feels almost effortless, for with the elimination of most carbs plus the medication I have ZERO cravings and minimal hunger. My cholesterol, blood pressure, and blood sugar have all returned to normal having previously been considerably elevated. I look and feel twenty years younger (I am 57.) Staff is friendly and supportive, and the science works. I did not think that I would be able to achieve such results, and certainly not in less than a year. I am amazed at my success, and I could not have done it without Dr. Tumpati and W8MD.”

- D.M., actual W8MD patient who lost 100 lbs and has maintained the weight loss for over 10 years. Individual results vary.

W8MD biggest loser success

W8MD has reported major success stories, including a biggest-loser result of more than 165 pounds lost. Individual results vary based on starting weight, adherence, medications, nutrition plan, medical conditions, follow-up, and maintenance care.

W8MD as a natural choice for total wellness

W8MD is a natural choice for patients who want weight loss connected to broader health and wellness. Unlike programs that only sell injections, W8MD can help evaluate and treat the factors that affect weight.

W8MD can help with:

W8MD locations

W8MD serves patients from New York City and Philadelphia offices, with service areas extending across the Northeast and Mid-Atlantic region.

Location Address Phone Services Map
Brooklyn / New York City Weight Loss and MedSpa Center 2632 E 21st Street, Suite L3, Brooklyn, NY 11235 (718) 946-5500 GLP-1 weight loss injections, Semaglutide, Tirzepatide, medical weight loss, sleep medicine, MedSpa, nutrition counseling View map
Philadelphia / Greater Philadelphia Weight Loss and MedSpa Center 1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115 (215) 676-2334 GLP-1 weight loss injections, Semaglutide, Tirzepatide, medical weight loss, sleep medicine, nutrition counseling, wellness services View map

Service areas

Frequently asked questions

Does W8MD offer Semaglutide for weight loss?

Yes. W8MD may offer Semaglutide-based weight-loss options for eligible patients when medically appropriate. Promotional pricing may start as low as $29.99/week and up with insurance for qualifying visits.

Does W8MD offer Tirzepatide for weight loss?

Yes. W8MD may offer Tirzepatide-based options for eligible patients when medically appropriate. Promotional pricing may start as low as $45.00/week and up with insurance for qualifying visits.

Does W8MD offer retatrutide?

Retatrutide is an investigational triple-action incretin medication as of 2026. W8MD can educate patients about emerging options, but patients should not buy unapproved retatrutide, research peptides, or online products. W8MD may consider future options when they become legally available and medically appropriate.

What makes W8MD different from online GLP-1 programs?

W8MD combines medical weight loss, nutrition counseling, sleep medicine, meal replacements, traditional medications, long-term maintenance, and in-person clinic support in addition to GLP-1 options.

Can W8MD help prevent weight regain?

Yes. W8MD emphasizes long-term follow-up, GLP-1 maintenance therapy, microdosing discussions when appropriate, diet pills when needed, nutrition counseling, sleep apnea care, and behavior modification.

Does W8MD accept insurance?

W8MD accepts most insurances for qualifying medical visits when coverage is available. Coverage, copays, deductibles, prior authorization, and medication benefits vary by plan.

Are GLP-1 medications safe?

GLP-1 medications can be safe and effective for eligible patients when prescribed and monitored by qualified clinicians, but they can have side effects and are not appropriate for everyone. Medical evaluation is required.

Conclusion

W8MD Weight Loss, Sleep and MedSpa offers affordable physician-supervised weight-loss care that may include Semaglutide starting as low as $29.99/week and up with insurance for qualifying visits, Tirzepatide starting as low as $45.00/week and up with insurance for qualifying visits, and other medical weight-loss options when medically appropriate. W8MD also monitors emerging incretin therapies such as retatrutide while emphasizing safety, FDA-approved treatment, and avoidance of unapproved research peptides. By combining GLP-1 shots, traditional prescription medications, nutrition counseling, meal replacements, sleep apnea care, lifestyle medicine, regular follow-up, and weight-maintenance support, W8MD is a natural choice for patients who want not only to lose weight but also to keep it off.

See also

Relevant WikiMD links

Further reading

  • FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.November 8, 2023.
  • FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.
  • FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.
  • FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss(link). U.S. Food and Drug Administration.June 15, 2026.
  • "Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.
  • Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial(link). Eli Lilly and Company.May 21, 2026.
  • "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension".Diabetes, Obesity and Metabolism.2022;PMID:35441470.PMC:9542252.
  • "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity".JAMA.2024;PMID:38078870.

External links



Retrieved from "https://w8md.com/w/index.php?title=Weight_loss_injections_Philadelphia&oldid=6294"